Study guide
10.4 Cardiovascular Pharmacology in Podiatric Patients
APMLE Part I Basic Sciences Podiatry
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & Lower Extremity Osteology
1.1 APMLE Part I Exam Structure, Policies & Scoring 1.2 Foot Osteology: Tarsals, Metatarsals, Phalanges & Sesamoids 1.3 Leg & Ankle Osteology: Tibia, Fibula & The Ankle Mortise 1.4 Pelvis, Femur & Patella Osteology: Landmarks & Biomechanics
2 Chapter 2: Lower Extremity Arthrology & Ligaments
2.1 Foot Articulations: Subtalar, Midtarsal, Lisfranc & Digital Joints 2.2 Talocrural (Ankle) & Knee Joints: Ligaments & Kinematics 2.3 Hip Joint & Pelvic Articulations: Capsular Structures & Dynamics
3 Chapter 3: Lower Extremity Myology & Compartments
3.1 Anterior & Lateral Compartments of the Leg 3.2 Superficial & Deep Posterior Compartments of the Leg 3.3 Plantar Layers & Intrinsic Musculature of the Foot 3.4 Thigh & Gluteal Musculature: Attachments & Innervations
4 Chapter 4: Lower Extremity Neurovascular & Topographical Anatomy
4.1 Lumbar & Sacral Plexuses, Peripheral Nerves & Dermatomes 4.2 Arterial Network, Venous Drainage & Lymphatics 4.3 Tarsal Tunnel, Femoral Triangle & Topographical Spaces
5 Chapter 5: Microbiology: Bacteriology, Zoonoses & Laboratory Methods
5.1 Gram-Positive Cocci & Bacilli in Podiatric Infections 5.2 Gram-Negative Bacilli & Opportunistic Pathogens 5.3 Anaerobic Pathogens & Diabetic Foot Infections 5.4 Bacterial Structure, Virulence Factors & Sterilization 5.5 Mycobacteria, Spirochetes, Mycoplasma & Zoonotic Infections 5.6 Antimicrobial Resistance, Susceptibility Testing, Specimen Handling & Vaccines
6 Chapter 6: Mycology, Virology, Parasitology & Clinical Immunology
6.1 Mycology: Dermatophytes, Onychomycosis & Systemic Mycoses 6.2 Clinically Relevant Viruses & Parasitic Infections 6.3 Innate & Adaptive Immunity Mechanisms 6.4 Hypersensitivity Reactions, Immunodeficiencies & Autoimmunity 6.5 Transplant & Tumor Immunology and Immunodiagnostic Methods
7 Chapter 7: General & Cellular Pathology
7.1 Cellular Injury, Adaptations & Cell Death Mechanisms 7.2 Acute vs Chronic Inflammation & Tissue Repair 7.3 Hemodynamic Disorders, Thrombosis, Embolism & Shock 7.4 Neoplasia, Oncogenes, Tumor Suppressors & Cutaneous Tumors
8 Chapter 8: Systemic & Podiatric Pathology
8.1 Atherosclerosis, Peripheral Artery Disease & Diabetic Microangiopathy 8.2 Osteoarthritis, Inflammatory Arthritides & Bone Infections 8.3 Neuropathic Disorders, Charcot Neuroarthropathy & Dermatopathology 8.4 Laboratory Diagnostics, Synovial Fluid & Biopsy Interpretation
9 Chapter 9: Organ-System Pathology
9.1 Anemias, Hemoglobinopathies, Leukemias & Immune Disorders 9.2 Cardiac & Pulmonary Pathology 9.3 Renal, Urogenital & Reproductive Pathology 9.4 Gastrointestinal, Hepatobiliary & Endocrine Pathology
10 Chapter 10: General Pharmacology, Autonomic Drugs & Toxicology
10.1 Pharmacokinetics, ADME & Receptor Dynamics 10.2 Cholinergic Agonists & Muscarinic/Nicotinic Antagonists 10.3 Adrenergic Agonists, Sympatholytics & Clinical Applications 10.4 Cardiovascular Pharmacology in Podiatric Patients 10.5 Drug Interactions, Adverse Effects, Pharmacogenomics & Toxicology
11 Chapter 11: Antimicrobial & Podiatric Therapeutics
11.1 Antibacterial Classes, Mechanisms & Resistances 11.2 Antifungal, Antiviral & Antiparasitic Therapeutics 11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents 11.4 Local & General Anesthetic Pharmacology
12 Chapter 12: Systemic Pharmacology
12.1 Anticonvulsants, Antidepressants, Psychotropics & Skeletal Muscle Relaxants 12.2 Insulin & Noninsulin Glycemic Agents 12.3 Respiratory & Gastrointestinal Agents 12.4 DMARDs, Biologics, Antineoplastics & Immunosuppressants 12.5 Hormone Therapy, Bisphosphonates, Antihistamines, Growth Factors & Complementary Agents
13 Chapter 13: General Anatomy: Systemic Gross Anatomy & Neuroanatomy
13.1 Cranial Nerves, Head & Neck Anatomy 13.2 Thoracic Wall, Tracheobronchial Tree, Lungs & Mediastinum 13.3 Abdominal Wall, GI Viscera, Pelvis & Retroperitoneum 13.4 Vertebral Column, Spinal Cord & Upper Extremity Overview 13.5 Neuroanatomy: CNS Organization, Somatosensory & Motor Pathways
14 Chapter 14: Histology, Integument, Embryology & Genetics
14.1 Microscopic Anatomy: Epithelia, Connective Tissue, Muscle & Nerve 14.2 Integumentary System: Dermis, Appendages, Nail Unit & Cutaneous Receptors 14.3 Embryogenesis, Limb Morphogenesis & Postnatal Development 14.4 Medical Genetics & Structural Alterations in Aging
15 Chapter 15: Cellular, Neuromuscular & Cardiovascular Physiology
15.1 Membrane Potential, Ion Channels & Transport Mechanisms 15.2 Action Potentials, Synaptic Transmission & Muscle Contraction 15.3 Cardiac Electrophysiology, ECG & Hemodynamics 15.4 Blood Pressure Regulation, Poiseuille Law & Capillary Dynamics
16 Chapter 16: Organ-System Physiology: Respiratory, Renal, Endocrine, GI & Blood
16.1 Pulmonary Mechanics, Gas Exchange & Acid-Base Regulation 16.2 Renal Filtration, Tubular Transport & Fluid/Acid-Base Balance 16.3 Endocrine Regulation, Reproductive Hormones, Calcium & Bone 16.4 Gastrointestinal & Hepatobiliary Physiology 16.5 Hematology: Erythropoiesis, Leukocytes, Platelets & Coagulation 16.6 Exercise Physiology, Thermoregulation & Bone Mechanobiology
17 Chapter 17: Biochemistry: Proteins, Enzymes, Carbohydrates & Signaling
17.1 Amino Acid Chemistry, Protein Structure & Enzyme Kinetics 17.2 Glycolysis, Gluconeogenesis, Glycogen Metabolism & TCA Cycle 17.3 Electron Transport Chain, ATP Synthesis & Metabolic Inborn Errors 17.4 Hormones, Receptors, Second Messengers & Signal Transduction
18 Chapter 18: Biochemistry: Lipids, Molecular Genetics, Blood Chemistry & Nutrition
18.1 Fatty Acid Oxidation, Ketogenesis, Cholesterol & Lipoproteins 18.2 Nucleotide Metabolism, DNA Replication, Transcription, Translation & Repair 18.3 Vitamins, Micronutrients & Inborn Errors of Metabolism 18.4 Blood Chemistry: Heme Metabolism, Hemoglobin & Plasma Proteins 18.5 Nutrition: Energy Balance, Glycemic Index, Fed-Fast Cycle & Free Radicals
10.4 Cardiovascular Pharmacology in Podiatric Patients
Key Takeaways Explain This Topic AI
ACE inhibitors selectively dilate the renal efferent arteriole to reduce intraglomerular pressure and retard diabetic nephropathy; accumulation of bradykinin and substance P causes their hallmark dry cough and angioedema, adverse effects bypassed by ARBs.
Dihydropyridine calcium channel blockers (amlodipine) induce dependent bilateral lower extremity edema via precapillary arteriolar vasodilation and elevated microvascular hydrostatic pressure; this represents a transudative hemodynamic mechanism rather than systemic volume overload or DVT.
Loop diuretics inhibit the NKCC2 cotransporter in the thick ascending limb, causing potent natriuresis, hypokalemia, and hyperuricemia that frequently triggers acute gouty arthritis in the first metatarsophalangeal joint.
Perioperative antiplatelet and anticoagulant management balances bleeding against thrombosis: aspirin irreversibly blocks platelet COX-1 for 7–10 days, clopidogrel requires 5–7 days withdrawal, and warfarin mandates a 5-day pause with reversal via 4-Factor PCC and Vitamin K when urgent.
Statins inhibit HMG-CoA reductase to upregulate LDL clearance and stabilize plaques in peripheral artery disease; co-administration with CYP3A4 inhibitors dramatically increases the risk of skeletal myopathy and rhabdomyolysis.
Last updated: October 2026
10.4 Cardiovascular Pharmacology in Podiatric Patients
Independent Study Guide Notice: Independent study guide by ExamFinch. This educational resource is developed independently by ExamFinch and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.
Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors
Patients presenting to podiatric clinics for diabetic limb salvage, reconstructive foot and ankle surgery, or peripheral vascular disease overwhelmingly carry comorbid hypertension, diabetes mellitus, and heart failure managed with RAAS antagonists. The RAAS Pathway & Drug Targets
- Angiotensinogen (Liver)
- │
- ▼ ◄─── [Renin] (Renal Juxtaglomerular Cells; Blocked by Aliskiren)
- Angiotensin I
- │
- ▼ ◄─── [ACE / Kininase II] (Pulmonary Endothelium; Blocked by ACE Inhibitors)
- Angiotensin II (Potent Vasoconstrictor; Efferent Arteriolar Constriction)
- │
- ├───────────────────────────────┬───────────────────────────────┐
- ▼ ▼ ▼
- AT1 Receptors Adrenal Cortex Bradykinin
- (Blocked by ARBs) (Aldosterone Secretion) (Degraded by ACE)
- │ │ │
- ▼ ▼ ▼
- Vasoconstriction Na+/H2O Retention (Late DCT) [Inhibited by ACEI]
- ↑ SVR & Afterload K+/H+ Excretion (Collecting) Accumulates → Cough &
- Efferent Constriction [Blocked by Spironolactone] Angioedema
- Angiotensin-Converting Enzyme (ACE) Inhibitors
Representative Agents: Lisinopril, Enalapril, Ramipril, Captopril, Benazepril.
Mechanism of Action: Competitively inhibit Angiotensin-Converting Enzyme (ACE) , a zinc metallopeptidase situated primarily on pulmonary vascular endothelial luminal membranes. ACE is identical to the enzyme kininase II .
Blocks conversion of inactive Angiotensin I → \rightarrow → active Angiotensin II , decreasing systemic vasoconstriction, total peripheral resistance, and blood pressure.
Reduces Angiotensin II-stimulated secretion of Aldosterone from the adrenal zona glomerulosa, promoting renal natriuresis while retaining potassium.
Inhibits Bradykinin and Substance P Degradation: Because ACE (kininase II) normally inactivates bradykinin, ACE inhibition causes dramatic systemic and airway accumulation of bradykinin and substance P.
Renal Hemodynamics & Diabetic Nephropathy Protection:
In healthy kidneys, Angiotensin II preferentially constricts the efferent arteriole of the glomerulus, elevating glomerular capillary hydrostatic pressure ( P G C P_{GC} P GC ) and preserving Glomerular Filtration Rate (GFR).
ACE inhibitors block this mechanism, producing selective efferent arteriolar vasodilation . This reduces intraglomerular capillary pressure, diminishes hyperfiltration injury, and significantly slows the progression of proteinuria and renal fibrosis in Diabetic Nephropathy .
Adverse Effects:
Dry, Non-Productive Cough (5% - 20%): Mediated by local bronchial accumulation of bradykinin, substance P, and prostaglandins irritating pulmonary sensory C-fibers. Unrelated to dose; resolves within 1–4 weeks of drug cessation.
Angioedema (0.1% - 0.7%): Rapid-onset, non-pitting, non-pruritic transudative swelling of the lips, tongue, pharynx, larynx, and face mediated by bradykinin-induced microvascular leakage . Can cause acute airway obstruction; contraindicated permanently if experienced.
Hyperkalemia: Reduced aldosterone decreases N a + / K + Na^+/K^+ N a + / K + exchange in the principal cells of the cortical collecting duct, elevating serum potassium.
Acute Decline in GFR in Bilateral Renal Artery Stenosis: In patients with severe bilateral renal artery stenosis (or stenosis in a solitary kidney), renal perfusion pressure is severely compromised, and GFR is maintained exclusively by Angiotensin II-mediated efferent arteriolar constriction. ACE inhibitors abruptly eliminate this efferent tone, precipitating an acute, dramatic drop in GFR and acute renal failure.
Teratogenicity: Causes fetal renal tubular dysgenesis, oligohydramnios, skull hypoplasia, and fetal demise (contraindicated in pregnancy).
Angiotensin Receptor Blockers (ARBs)
Representative Agents: Losartan, Valsartan, Candesartan, Irbesartan.
Mechanism of Action: Potent, competitive antagonists that selectively block the Angiotensin II Type 1 ( A T 1 AT_1 A T 1 ) receptor . They block all downstream actions of Angiotensin II (vasoconstriction, aldosterone release, vascular remodeling) without altering ACE activity.
Clinical Distinction from ACEIs: Because ARBs do not inhibit kininase II , they do NOT cause accumulation of bradykinin or substance P . Consequently, ARBs do not cause the dry brassy cough characteristic of ACE inhibitors and exhibit a markedly lower incidence of angioedema. They are the drug of choice for patients requiring RAAS blockade who develop ACEI-induced cough. They share the same risks of hyperkalemia, acute GFR drops in renal artery stenosis, and teratogenicity.
Calcium Channel Blockers (CCBs) & The Podiatric Edema Pearl
Calcium channel blockers inhibit voltage-gated L-type (long-lasting) calcium channels ( C a V 1.2 Ca_V1.2 C a V 1.2 ) in cardiac myocytes, specialized conducting nodal tissue, and vascular smooth muscle, decreasing intracellular calcium entry and inhibiting contraction.
Dihydropyridine vs. Non-Dihydropyridine CCBs
CCB Subclass Representative Agents Primary Tissue Selectivity Clinical Utility Major Adverse Effects
Dihydropyridines (DHPs) Amlodipine, Nifedipine, Nicardipine, Felodipine Vascular Smooth Muscle >>> Cardiac (Potent arteriolar vasodilators with negligible direct nodal effects at clinical doses) First-line systemic hypertension, chronic stable angina, Raynaud phenomenon Dependent lower extremity edema , reflex tachycardia, facial flushing, headache, gingival hyperplasia
Non-Dihydropyridines (Non-DHPs) Verapamil (Phenylalkylamine) Cardiac Myocardium >>> Vascular (Greatest negative inotropic and dromotropic activity) Rate control in atrial fibrillation / flutter, PSVT prophylaxis, angina Severe constipation (blocks colonic motility), bradycardia, AV block, worsening of systolic heart failure
Non-Dihydropyridines (Non-DHPs) Diltiazem (Benzothiazepine) Intermediate (Balanced cardiac depression and peripheral arteriolar vasodilation) Rate control in atrial fibrillation, angina, hypertension Bradycardia, conduction abnormalities, peripheral edema (less than DHPs), CYP3A4 inhibition
Important
The Podiatric Board Pearl: Amlodipine-Induced Lower Extremity Edema Podiatric physicians are frequently consulted to evaluate bilateral lower extremity swelling in elderly or diabetic hypertensive patients. A classic clinical presentation involves a patient taking amlodipine (5 to 10 mg daily) who presents with progressive, bilateral, pitting dependent ankle and pretibial edema without signs of systemic fluid overload.
Physiologic Mechanism: Dihydropyridine CCBs act as potent, selective precapillary arteriolar vasodilators , but have virtually no vasodilatory effect on postcapillary venules . This asymmetric precapillary dilation exposes delicate downstream capillary beds to higher systemic arterial pressures, resulting in a marked increase in microvascular capillary hydrostatic pressure ( P c P_c P c ) .
Transudative Fluid Shift: According to the Starling equation ( J v = K f [ ( P c − P i ) − σ ( π c − π i ) ] J_v = K_f [(P_c - P_i) - \sigma (\pi_c - \pi_i)] J v = K f [( P c − P i ) − σ ( π c − π i )] ), elevated P c P_c P c drives transudation of protein-poor fluid out of the vascular space and into the interstitial tissue of the lower extremities, exacerbated by gravity in dependent limbs.
Crucial Diagnostic & Therapeutic Distinction: This edema is transudative and hemodynamic , NOT caused by renal sodium retention, systemic hypervolemia, right-sided congestive heart failure, or deep venous thrombosis. Consequently, loop diuretics (furosemide) are clinically ineffective and risk volume depletion and acute kidney injury. The definitive management is to reduce the amlodipine dose, discontinue the agent, or co-administer an ACE inhibitor or ARB (which promotes balanced postcapillary venular dilation, normalizing capillary hydrostatic pressure and resolving the edema).
Loading diagram... Hemodynamic Mechanism of Amlodipine-Induced Lower Extremity Edema
Diuretic Pharmacotherapy & Podiatric Board Correlations
Diuretics alter tubular solute and water transport along distinct nephron segments. Their metabolic and electrolyte disturbances directly affect lower extremity clinical presentations, particularly gout and wound healing . Nephron Diuretic Sites
- Glomerulus
- │
- ├─► Proximal Convoluted Tubule: Carbonic Anhydrase Inhibitors (Acetazolamide)
- │
- ├─► Thick Ascending Limb (Loop of Henle): Loop Diuretics (Furosemide, Torsemide)
- │ [Inhibits NKCC2 Cotransporter; Causes 'Loops Lose Calcium']
- │
- ├─► Early Distal Convoluted Tubule: Thiazide Diuretics (HCTZ, Chlorthalidone)
- │ [Inhibits NCCT Cotransporter; Causes Calcium Retention]
- │
- └─► Cortical Collecting Tubule: K+-Sparing Diuretics (Spironolactone, Amiloride)
- [Inhibits Aldosterone / ENaC; Causes Hyperkalemia]
- Loop Diuretics: Furosemide, Bumetanide, Torsemide, Ethacrynic Acid
Mechanism: Reversibly inhibit the N a + / K + / 2 C l − Na^+/K^+/2Cl^- N a + / K + /2 C l − cotransporter (NKCC2) localized to the luminal membrane of the thick ascending limb of the loop of Henle . By halting sodium and chloride reabsorption, they eliminate the hypertonic medullary osmotic gradient, rendering the collecting duct unable to concentrate urine and inducing profound, rapid natriuresis.
Calcium Handling: Disruption of the NKCC2 transporter halts the back-diffusion of potassium into the tubular lumen, abolishing the positive lumen-potential ( + 10 mV +10\text{ mV} + 10 mV ) that normally drives paracellular reabsorption of divalent cations. Consequently, "Loops Lose Calcium" , leading to increased urinary calcium excretion (useful in hypercalcemia crisis).
High-Yield Adverse Effects:
Hypokalemic, hypochloremic metabolic alkalosis and hypomagnesemia.
Hyperuricemia & Acute Gout Precipitation: Loop diuretics induce volume depletion, which stimulates proximal tubular reabsorption of urate. Furthermore, loop diuretics actively compete with uric acid for secretory organic acid transporters (OAT1/3) in the proximal tubule. This elevates serum uric acid, frequently precipitating an acute attack of gouty arthritis (podagra) in the first metatarsophalangeal joint of podiatric patients.
Ototoxicity: Dose-dependent damage to hair cells within the stria vascularis of the inner ear, presenting with tinnitus, vertigo, and reversible or permanent sensorineural hearing loss; exacerbated when combined with aminoglycosides .
Sulfa Allergy: Furosemide, bumetanide, and torsemide contain a sulfonamide moiety. In patients with severe sulfa allergy, the non-sulfonamide phenoxyacetic acid derivative Ethacrynic Acid must be utilized.
Thiazide Diuretics: Hydrochlorothiazide, Chlorthalidone, Metolazone
Mechanism: Inhibit the N a + / C l − Na^+/Cl^- N a + / C l − cotransporter (NCCT) in the luminal membrane of the early distal convoluted tubule (DCT) .
Calcium Handling: In sharp contrast to loop diuretics, thiazides enhance calcium reabsorption in the DCT by lowering intracellular sodium and stimulating the basolateral N a + / C a 2 + Na^+/Ca^{2+} N a + / C a 2 + exchanger. This produces hypercalcemia (beneficial in osteopenic elderly patients and for preventing calcium oxalate nephrolithiasis).
High-Yield Adverse Effects:
Hyperuricemia: Competes for organic acid excretion and elevates urate reabsorption, triggering acute gout attacks.
Hyperglycemia: Impairs pancreatic insulin release and decreases peripheral tissue glucose utilization; requires close glycemic monitoring in diabetic patients.
Hyperlipidemia, Hypokalemia, Hyponatremia.
Potassium-Sparing Diuretics
Aldosterone Receptor Antagonists (Spironolactone, Eplerenone): Competitive inhibitors of cytoplasmic mineralocorticoid receptors in the principal cells of the cortical collecting tubule. Prevents aldosterone from upregulating epithelial sodium channels (ENaC) and basolateral N a + / K + Na^+/K^+ N a + / K + ATPases. Diminishes morbidity and mortality in severe systolic heart failure (HFrEF).
Adverse Effects: Hyperkalemia and metabolic acidosis. Spironolactone is a non-selective steroid antagonist that binds androgen and progesterone receptors, causing gynecomastia, breast tenderness, and erectile dysfunction in males. Eplerenone is highly selective for mineralocorticoid receptors and does not cause antiandrogenic side effects.
Direct ENaC Blockers (Amiloride, Triamterene): Directly block luminal epithelial sodium channels (ENaC) in the collecting tubule, preventing sodium influx and secondary potassium excretion. Major risk: hyperkalemia (especially when combined with ACE inhibitors or NSAIDs).
Perioperative Anticoagulant & Antiplatelet Management
Podiatric surgeons routinely manage complex patients undergoing elective foot and ankle reconstructions, trauma ORIF, or limb salvage who are receiving chronic antiplatelet or anticoagulant therapy. Balancing thromboembolic prevention against intraoperative hemorrhage, wound hematoma, and compartment syndrome requires adherence to verified perioperative timelines.
Antiplatelet Pharmacology & Perioperative Timing
Antiplatelet Agent Target & Molecular Mechanism Platelet Effect Duration Perioperative Management & Reversal
Aspirin (ASA) Irreversibly acetylates Cyclooxygenase-1 (COX-1) , permanently blocking synthesis of Thromboxane A 2 A_2 A 2 ( T X A 2 TXA_2 TX A 2 ) . Entire lifespan of platelet ( 7 to 10 days ); platelets lack nuclei and cannot synthesize new enzymes. For low-risk minor podiatric soft tissue procedures, aspirin is often continued; for major osteotomies or reconstructive surgery, hold 7 to 10 days preoperatively . In emergencies, reverse with platelet transfusion .
Clopidogrel (Plavix), Prasugrel, Ticagrelor P 2 Y 12 P2Y_{12} P 2 Y 12 ADP Receptor Antagonists: Inhibit ADP-mediated activation of the Glycoprotein IIb/IIIa (GP IIb/IIIa) complex , preventing fibrinogen cross-linking. Clopidogrel and Prasugrel are irreversible ( 5 to 7 days ); Ticagrelor is reversible. Hold 5 to 7 days prior to elective surgery . Clopidogrel is an inactive prodrug requiring two-step hepatic bioactivation by CYP2C19 (poor metabolizers or patients on omeprazole have reduced efficacy).
Cilostazol Phosphodiesterase-3 (PDE3) Inhibitor: Increases intracellular cyclic AMP ( c A M P cAMP c A MP ) in platelets and vascular smooth muscle → \rightarrow → inhibits platelet aggregation and produces potent peripheral vasodilation . Reversible; short elimination half-life First-line pharmacotherapy for intermittent claudication in Peripheral Artery Disease (PAD) ; hold 2–3 days preoperatively. Contraindicated in Congestive Heart Failure of any severity (increases mortality).
Anticoagulant Pharmacology, Monitoring & Reversal Protocols
Anticoagulant Primary Molecular Target Routine Lab Monitoring Perioperative Hold Time Specific Reversal Agents
Unfractionated Heparin (UFH) Binds Antithrombin III (ATIII) via pentasaccharide sequence; accelerates ATIII inactivation of Thrombin (IIa) and Factor Xa by 1,000-fold. aPTT (Intrinsic pathway; goal 1.5–2.5x control) Discontinue 4 to 6 hours preoperatively (rapid clearance; t 1 / 2 ≈ 1 − 2 hrs t_{1/2} \approx 1 - 2\text{ hrs} t 1/2 ≈ 1 − 2 hrs ) Protamine Sulfate: Positively charged basic peptide that stoichiometrically binds and neutralizes negatively charged heparin.
Low-Molecular-Weight Heparin (LMWH: Enoxaparin) Accelerates ATIII inactivation primarily of Factor Xa > Thrombin (ratio 3:1 to 4:1); smaller polysaccharide chain. None routinely; Anti-Xa level in severe renal failure, obesity, or pregnancy Hold 12 hours for prophylactic dosing; hold 24 hours for therapeutic dosing prior to surgery Protamine Sulfate (provides partial reversal, neutralizing ~60% of anti-Xa activity).
Warfarin (Coumadin) Inhibits Vitamin K Epoxide Reductase Complex 1 (VKORC1) ; prevents γ \gamma γ -carboxylation of glutamic acid residues on Factors II, VII, IX, X, and Proteins C and S . PT / INR (Extrinsic pathway; therapeutic target 2.0–3.0) Discontinue 5 days preoperatively (target INR < 1.5 < 1.5 < 1.5 for major orthopedic surgery) 4-Factor Prothrombin Complex Concentrate (4F-PCC) for immediate reversal (contains Factors II, VII, IX, X); IV Vitamin K (Phytonadione) re-stimulates hepatic synthesis (6–24 hrs).
Direct Factor Xa Inhibitors (Apixaban, Rivaroxaban) Directly and reversibly bind the active catalytic site of Factor Xa (both free and clot-bound). None routinely; specific Anti-Xa assays available Hold 24 to 48 hours preoperatively (hold 48–72 hrs in patients with renal impairment / CrCl < 50 mL/min < 50\text{ mL/min} < 50 mL/min ) 4-Factor PCC for life-threatening bleeding. Andexanet alfa, a recombinant decoy Factor Xa, was withdrawn from the U.S. market in December 2025.
Direct Thrombin Inhibitor (Dabigatran / Pradaxa) Binds directly and reversibly to the active catalytic site of Free and Clot-Bound Thrombin (Factor IIa) . Thrombin Time (TT), dilute Russell viper venom time Hold 24 to 48 hours preoperatively (hold 48–72 hrs if CrCl < 50 mL/min < 50\text{ mL/min} < 50 mL/min ) Idarucizumab (Praxbind): Humanized monoclonal antibody fragment (Fab) that binds dabigatran with 350x higher affinity than thrombin.
Loading diagram... Coagulation Cascade Targets, Anticoagulant Mechanisms, and Reversal Agents
High-Yield Anticoagulant Complications
Caution
Heparin-Induced Thrombocytopenia (HIT Type II): HIT Type II is a life-threatening, immune-mediated adverse reaction occurring 5 to 10 days following heparin exposure (or earlier with recent re-exposure):
Pathophysiology: Patients synthesize IgG autoantibodies directed against complexes of Platelet Factor 4 (PF4) and Heparin . These immune complexes bind to the F c γ R I I A Fc\gamma RIIA F c γ R II A receptors on circulating platelets, triggering massive, uncontrolled platelet activation, systemic degranulation, and consumption.
Clinical Presentation: Marked drop in platelet count by ≥ 50 % \ge 50\% ≥ 50% from baseline (often dropping to 30 , 000 − 60 , 000 / μ L 30,000 - 60,000/\mu\text{L} 30 , 000 − 60 , 000/ μ L ). Crucially, despite severe thrombocytopenia, patients do not bleed; instead, the massive platelet activation produces catastrophic arterial and venous thrombosis (White Clot Syndrome) , leading to acute limb ischemia, digital gangrene, DVT, pulmonary embolism, and stroke.
Immediate Management:
Immediately discontinue ALL forms of heparin (including UFH, LMWH, and heparin flushes).
Initiate non-heparin anticoagulation using a Direct Thrombin Inhibitor (Argatroban or Bivalirudin) . Argatroban is cleared hepatically and is the agent of choice in renal failure.
NEVER start Warfarin during acute HIT! Warfarin rapidly depletes Protein C, producing an acute transient prothrombotic state that triggers microvascular thrombosis and venous limb gangrene ; warfarin can only be introduced after the platelet count has fully recovered ( > 150 , 000 / μ L > 150,000/\mu\text{L} > 150 , 000/ μ L ) under continuous direct thrombin inhibitor coverage.
Note
Warfarin-Induced Skin Necrosis: Warfarin blocks synthesis of Factors II, VII, IX, and X, as well as the endogenous anticoagulant Proteins C and S . Protein C has a very short half-life (~8 hours), comparable to Factor VII, whereas procoagulant prothrombin (Factor II) has a long half-life (~60 to 72 hours). During the first 24 to 48 hours of warfarin therapy, Protein C levels plummet rapidly while procoagulant factors remain active, creating an early, transient hypercoagulable state . In patients with underlying heterozygous Protein C or S deficiency, this causes microvascular thrombosis in cutaneous venules, leading to hemorrhagic infarction and skin necrosis (typically in adipose-rich areas: breasts, buttocks, thighs). This catastrophe is prevented by "bridging" with therapeutic heparin or LMWH for at least 4 to 5 days until a therapeutic INR (2.0–3.0) is achieved for at least 24 hours.
- Lipid-Lowering Pharmacotherapy (Statins)
- HMG-CoA Reductase Inhibitors
Representative Agents: Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin.
Molecular Mechanism: Statins act as structural analogs of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) and competitively inhibit HMG-CoA Reductase , the rate-limiting enzyme in hepatic de novo cholesterol biosynthesis ( H M G - C o A → Mevalonate HMG\text{-}CoA \rightarrow \text{Mevalonate} H MG - C o A → Mevalonate ).
Downstream Cellular Cascade: Depletion of intracellular hepatic cholesterol triggers the activation of Sterol Regulatory Element-Binding Protein 2 (SREBP-2), which upregulates transcription of cell-surface LDL Receptors (LDL-R) on hepatocytes. Increased LDL receptor density drives massive endocytic clearance of circulating apoB-100-containing low-density lipoproteins, reducing serum LDL-C by 30 % − 60 % 30\% - 60\% 30% − 60% .
Pleiotropic Effects in Peripheral Artery Disease: Beyond lipid reduction, statins exert powerful pleiotropic vascular benefits: they improve endothelial function (upregulate eNOS), inhibit vascular smooth muscle proliferation, stabilize vulnerable atherosclerotic fibrous caps, and suppress inflammatory cytokines. High-intensity statin therapy reduces all-cause mortality, major adverse cardiovascular events (MACE), and major adverse limb events (MALE / amputations) in patients with peripheral artery disease.
Adverse Effects & Drug Interactions:
Hepatotoxicity: Elevation in serum aminotransferases (AST/ALT); baseline LFTs checked prior to initiation.
Statin-Associated Muscle Symptoms (SAMS) & Rhabdomyolysis: Manifests as bilateral proximal muscle weakness, soreness, and myalgias. In severe cases, it progresses to rhabdomyolysis , marked by massive elevations in serum creatine kinase ( C K > 10 x CK > 10\text{x} C K > 10 x upper limit of normal), dark tea-colored urine (myoglobinuria), and acute tubular necrosis.
CYP3A4 Drug-Drug Interactions: Simvastatin, lovastatin, and atorvastatin are metabolized extensively by hepatic Cytochrome P450 3A4 (CYP3A4) . Concomitant administration of potent CYP3A4 inhibitors—particularly azole antifungals (itraconazole, ketoconazole, fluconazole) , macrolide antibiotics (erythromycin, clarithromycin) , protease inhibitors, or gemfibrozil (which inhibits statin glucuronidation)—markedly reduces statin clearance, escalating plasma concentrations by up to 10-fold and precipitating severe, life-threatening rhabdomyolysis. In patients requiring systemic azole therapy for onychomycosis or deep mycotic foot infections, statins must be temporarily held or switched to pravastatin or rosuvastatin (which are not metabolized via CYP3A4).
Cardiac Glycosides, Antiarrhythmics, Antianginals, Vasodilators & Fibrinolytics
The pharmacology outline's cardiovascular heading also lists cardiac glycosides, antiarrhythmics, antianginals, fibrinolytics and vasodilators.
Digoxin (cardiac glycoside).
Mechanism: inhibits the Na+/K+-ATPase. Intracellular Na+ rises, the Na+/Ca2+ exchanger removes less calcium, and contractility increases. Digoxin also raises vagal tone, slowing AV conduction, which is why it is used for rate control in atrial fibrillation.
Toxicity: nausea and vomiting, confusion, yellow-green visual halos and arrhythmias such as atrial tachycardia with block or bidirectional ventricular tachycardia. It has a narrow therapeutic index.
Risk factors: hypokalemia from loop or thiazide diuretics (potassium normally competes with digoxin at the pump), renal impairment, and interacting drugs such as amiodarone, verapamil and clarithromycin.
Antidote: digoxin immune Fab. Hyperkalemia signals severe acute toxicity.
Antiarrhythmics (Vaughan Williams classes):
Class Mechanism Examples Key toxicities
IA Na+ channel block; prolongs the action potential Quinidine, procainamide Cinchonism (quinidine); drug-induced lupus (procainamide); QT prolongation
IB Na+ channel block; shortens the action potential; acts on ischemic tissue Lidocaine , mexiletine CNS toxicity, as with local anesthetic systemic toxicity
- IC Strong Na+ channel block Flecainide, propafenone Proarrhythmic in structural or ischemic heart disease
- II Beta-blockade Metoprolol, esmolol Bradycardia, bronchospasm, masked hypoglycemia
III K+ channel block; prolongs repolarization Amiodarone , sotalol, dofetilide Amiodarone: pulmonary fibrosis, hypo- or hyperthyroidism, hepatotoxicity, corneal deposits, blue-gray skin, photosensitivity, and higher warfarin and digoxin levels. Sotalol and dofetilide: torsades de pointes
IV Non-dihydropyridine Ca2+ channel block Verapamil, diltiazem Bradycardia, AV block, constipation
Other Adenosine (transient AV block for supraventricular tachycardia); magnesium (torsades) Adenosine: flushing, chest discomfort, brief asystole
Antianginals.
Nitrates (nitroglycerin, isosorbide mononitrate) release nitric oxide, which raises cGMP and dilates veins, reducing preload and myocardial oxygen demand. Adverse effects include headache, hypotension and reflex tachycardia. Tolerance requires a daily nitrate-free interval. Nitrates are contraindicated with PDE5 inhibitors (sildenafil, tadalafil) because together they cause severe hypotension.
Beta-blockers lower heart rate and contractility, calcium channel blockers lower afterload and relieve coronary spasm, and ranolazine inhibits the late sodium current.
Vasodilators.
Hydralazine is an arteriolar dilator. It causes reflex tachycardia, fluid retention and drug-induced lupus. Combined with isosorbide dinitrate, it benefits Black patients with heart failure with reduced ejection fraction.
Minoxidil opens K-ATP channels. It causes edema, hypertrichosis and pericardial effusion.
Nitroprusside dilates both arteries and veins. Prolonged infusion can cause cyanide toxicity.
Drugs for claudication and PAD.
Cilostazol is a PDE3 inhibitor that dilates arteries, inhibits platelets and improves walking distance. It carries a boxed warning against use in heart failure of any severity , and CYP3A4 and CYP2C19 inhibitors raise its levels.
Pentoxifylline is no longer recommended for claudication because it is not effective.
Statins and antiplatelet therapy reduce cardiovascular events in PAD. Low-dose rivaroxaban (2.5 mg twice daily) with aspirin reduces major cardiovascular and limb events.
Fibrinolytics.
Alteplase and tenecteplase convert plasminogen to plasmin, which degrades fibrin.
Uses include acute ischemic stroke, STEMI when timely PCI is unavailable, massive pulmonary embolism and catheter-directed treatment of acute limb ischemia.
The major risk is bleeding, including intracranial hemorrhage. Contraindications include active bleeding, prior hemorrhagic stroke and recent major surgery or trauma.
Bleeding is managed by stopping the infusion and giving cryoprecipitate (fibrinogen) and an antifibrinolytic such as tranexamic acid or aminocaproic acid.